Published in J Urol on April 01, 1987
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest (1999) 6.32
Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A (1987) 4.83
A heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement membrane. Am J Pathol (1988) 3.72
The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem (1992) 2.85
Permissive effect of the extracellular matrix on cell proliferation in vitro. Proc Natl Acad Sci U S A (1980) 2.71
Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry (1989) 2.49
Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med (1998) 2.42
Hereditary haemorrhagic telangiectasia. Haemophilia (2008) 2.22
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem (1997) 2.12
Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A (1996) 2.12
Heparanase as mediator of angiogenesis: mode of action. FASEB J (2001) 2.04
Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res (1983) 2.04
Surgical aspects of gastrointestinal persimmon phytobezoar treatment. Am J Surg (1986) 2.01
Bupivacaine wound instillation via an electronic patient-controlled analgesia device and a double-catheter system does not decrease postoperative pain or opioid requirements after major abdominal surgery. Anesth Analg (2001) 1.96
Morphological appearance, growth behavior and migratory activity of human tumor cells maintained on extracellular matrix versus plastic. Cell (1980) 1.94
Functional evaluation following microvascular oromandibular reconstruction of the oral cancer patient: a comparative study of reconstructed and nonreconstructed patients. Laryngoscope (1991) 1.85
Growth cycle of predacious Bdellovibrios in a host-free extract system and some properties of the host extract. J Bacteriol (1974) 1.80
Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem (1995) 1.78
Is prevaccination screening for hepatitis B among sexually active adolescents cost-effective? Clin Infect Dis (1998) 1.74
Expression of basic fibroblast growth factor in normal human tissues. Lab Invest (1990) 1.70
Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int (2007) 1.70
Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res (2001) 1.67
Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res (2000) 1.59
Respective roles of laminin and fibronectin in adhesion of human carcinoma and sarcoma cells. Nature (1981) 1.59
Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem (1999) 1.58
Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul (1990) 1.55
Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia (2007) 1.54
A two-domain mechanism for group A streptococcal adherence through protein F to the extracellular matrix. EMBO J (1996) 1.54
A comparison of the binding of epidermal growth factor to cultured granulosa and luteal cells. J Biol Chem (1978) 1.53
Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52
Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur J Cancer (1992) 1.51
Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases. Urology (1981) 1.47
Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem (1998) 1.47
Aortic endothelial cells synthesize basic fibroblast growth factor which remains cell associated and platelet-derived growth factor-like protein which is secreted. J Cell Physiol (1987) 1.44
Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost (2006) 1.44
Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature (1984) 1.42
Intravesical lidocaine: topical anesthesia for bladder mucosal biopsies. J Urol (1992) 1.41
Modulation of outflow resistance by the pores of the inner wall endothelium. Invest Ophthalmol Vis Sci (1992) 1.40
Isolated pulmonary blast injury in rats--a new model using the extracorporeal shock-wave lithotriptor. Mil Med (1989) 1.39
Screening for prostate cancer. Isr J Med Sci (1995) 1.38
Extradural bupivacaine and methadone for extracorporeal shock-wave lithotripsy. Br J Anaesth (1989) 1.37
Refractive power of premature children at infancy and early childhood. Am J Ophthalmol (1980) 1.37
Role of contact inhibition in the regulation of receptor-mediated uptake of low density lipoprotein in cultured vascular endothelial cells. Proc Natl Acad Sci U S A (1978) 1.36
Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol (1997) 1.34
Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells. Cancer Res (1989) 1.33
A past mutation at isoleucine 397 is now a common cause of moderate/mild haemophilia B. Br J Haematol (1990) 1.29
Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. J Clin Invest (1985) 1.27
Noninvasive detection of bladder cancer with the BTA stat test. J Urol (1999) 1.26
Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood (1987) 1.26
Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res (1994) 1.26
A homozygous chromosomal variant. Lancet (1969) 1.26
Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH. J Exp Med (1995) 1.24
Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest (1992) 1.23
Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action. Cell Regul (1990) 1.22
Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol (1990) 1.22
Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology (2004) 1.22
Epidermal growth factor and expression of specific genes: effects on cultured rat pituitary cells are dissociable from the mitogenic response. Proc Natl Acad Sci U S A (1980) 1.21
Regulation of adhesion of CD4+ T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1 beta. J Immunol (1994) 1.21
Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost (2006) 1.21
Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix. J Cell Physiol (1987) 1.19
Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J (2000) 1.18
The identification and localization of fibronectin in cultured corneal endothelial cells: cell surface polarity and physiological implications. Exp Eye Res (1979) 1.17
Vascular endothelial cells maintained in the absence of fibroblast growth factor undergo structural and functional alterations that are incompatible with their in vivo differentiated properties. J Cell Biol (1979) 1.16
Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J Biol Chem (1994) 1.15
Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res (1991) 1.14
Genetic analysis of Tourette syndrome suggesting major gene effect. Am J Hum Genet (1981) 1.14
Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence. J Biol Chem (2001) 1.14
Diagnosis and management of renal angiomyolipoma. Urology (1985) 1.14
Nuclear accumulation of epidermal growth factor in cultured rat pituitary cells. Nature (1980) 1.13
Heparanase in glomerular diseases. Kidney Int (2007) 1.13
Olfactory sensitivity, nasal resistance, and autonomic function in patients with multiple chemical sensitivities. Arch Otolaryngol Head Neck Surg (1988) 1.12
Effect of contact inhibition on the regulation of cholesterol metabolism in cultured vascular endothelial cells. J Biol Chem (1979) 1.11
Increased expression of heparanase in overt diabetic nephropathy. Kidney Int (2006) 1.11
Membrane changes and adenosine triphosphate content in normal and malignant transformed cells. Proc Natl Acad Sci U S A (1973) 1.11
Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia (2003) 1.10
Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol (1998) 1.10
Segmental testicular infarction due to sickle cell disease. J Urol (1998) 1.10
The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. FEBS Lett (1995) 1.09
Identification of glypican as a dual modulator of the biological activity of fibroblast growth factors. J Biol Chem (1997) 1.08
Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia (1999) 1.08
The extracellular matrix and the control of proliferation of vascular endothelial and vascular smooth muscle cells. J Supramol Struct (1980) 1.08
Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells. Int J Cancer (1985) 1.08
Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer (1999) 1.08
Tumor cell attachment to the vascular endothelium and subsequent degradation of the subendothelial extracellular matrix. Exp Cell Res (1982) 1.08
Tail vein assay of cancer metastasis. Curr Protoc Cell Biol (2001) 1.07
Tumor suppressor p53 regulates heparanase gene expression. Oncogene (2006) 1.07
B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia (2005) 1.07
Psychophysical evidence for post-receptoral sensitivity loss in diabetics. Invest Ophthalmol Vis Sci (1992) 1.07
The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells. Exp Cell Res (1985) 1.06
Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. Blood (1993) 1.06
The analgesic efficacy of patient-controlled ropivacaine instillation after Cesarean delivery. Anesth Analg (2000) 1.06
Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. J Clin Invest (1989) 1.06
An Arg-Gly-Asp sequence within thrombin promotes endothelial cell adhesion. J Cell Biol (1991) 1.05